As of March 31, Applied Therapeutics (APLT, Financial) reported cash and cash equivalents alongside short-term investments amounting to $50.8 million, a decrease from $79.4 million recorded on December 31, 2024. The company remains committed to achieving its operational, regulatory, and clinical objectives, with particular emphasis on advancing govorestat across various indications. This medication is anticipated to address significant unmet needs for patients suffering from rare diseases. The firm is actively preparing for potential regulatory engagements concerning both CMT-SORD and Classic Galactosemia treatments.
Under the leadership of Les Funtleyder, the Interim CEO and CFO, APLT believes it is well-equipped to handle these priorities effectively. In the immediate future, the company plans to present comprehensive 12-month clinical data from its Phase 3 INSPIRE study focused on CMT-SORD deficiency at the upcoming Peripheral Nerve Society Annual Meeting. Additionally, it will disclose new topline data collected over 18 and 24 months from patients before transitioning them into the open-label extension study.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Applied Therapeutics Inc (APLT, Financial) is $2.88 with a high estimate of $5.00 and a low estimate of $1.50. The average target implies an upside of 553.26% from the current price of $0.44. More detailed estimate data can be found on the Applied Therapeutics Inc (APLT) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Applied Therapeutics Inc's (APLT, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
